

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM472800

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
ROYAL BANK OF CANADA, as collateral agent		05/04/2018	Bank: CANADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Impax Laboratories, Inc.		
<b>Street Address:</b>	2 WALNUT GROVE DRIVE, SUITE 190		
<b>City:</b>	HORSHAM		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19044		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	Amedra Pharmaceuticals LLC		
<b>Street Address:</b>	2 WALNUT GROVE DRIVE, SUITE 190		
<b>City:</b>	HORSHAM		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19044		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Name:</b>	CorePharma L.L.C.		
<b>Street Address:</b>	2 WALNUT GROVE DRIVE, SUITE 190		
<b>City:</b>	HORSHAM		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19044		
<b>Entity Type:</b>	Limited Liability Company: NEW JERSEY		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4782446	RYTARY	
<b>Serial Number:</b>	86274525	PYNVRM	
<b>Serial Number:</b>	86274536	EMVERM	
<b>Serial Number:</b>	86337063	PERIACTIN	
<b>Serial Number:</b>	86511726	MYRYTARY	
<b>Serial Number:</b>	86517414	IMPAX	

CH \$165.00 4782446

**CORRESPONDENCE DATA****Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212-318-6532  
**Email:** alanagramer@paulhastings.com  
**Correspondent Name:** Alana Gramer  
**Address Line 1:** c/o Paul Hastings LLP  
**Address Line 2:** 200 Park Avenue, 28th Floor  
**Address Line 4:** New York, NEW YORK 10166

<b>NAME OF SUBMITTER:</b>	ALANA GRAMER
<b>SIGNATURE:</b>	/s/ AG
<b>DATE SIGNED:</b>	05/04/2018

**Total Attachments: 3**

source=Trademark Release 2#page1.tif  
source=Trademark Release 2#page2.tif  
source=Trademark Release 2#page3.tif

## **RELEASE OF SECURITY INTEREST IN TRADEMARKS**

This **RELEASE OF SECURITY INTEREST IN TRADEMARKS** (this "Release") is dated as of May 4, 2018 and delivered by Royal Bank of Canada, in its capacity as Collateral Agent (in such capacity, the "Collateral Agent"), in favor of the Grantors. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Trademark Security Agreement (as defined below) and if not defined therein, then the meanings given in the Security Agreement (as defined below) or the Credit Agreement (as defined below), as the case may be.

**WHEREAS**, pursuant to that certain Credit Agreement dated as of August 4, 2015 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Credit Agreement"), each Grantor and the Collateral Agent entered into that certain Security Agreement dated as of August 4, 2015 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Security Agreement") and that certain Trademark Security Agreement, dated as of February 29, 2016 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Trademark Security Agreement");

**WHEREAS**, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on March 2, 2016 at Reel/Frame 5750/0969.

**WHEREAS**, pursuant to the Security Agreement, each Grantor granted to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, including in all of such Grantor's right, title and interest in, to and under the Trademarks set forth on Schedule A attached hereto (collectively, the "Trademark Collateral").

**WHEREAS**, the Collateral Agent acknowledges the full payment and performance of the Obligations, and as a result desires to terminate and release the security interest in the Trademark Collateral.

**NOW, THEREFORE**, for and in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent, on behalf of itself and the Secured Parties, hereby (i) terminates, cancels, releases and forever discharges the security interest in the Trademark Collateral, (ii) terminates the Trademark Security Agreement, and (iii) retransfers and reassigns to each Grantor, as applicable and without representation or warranty of any kind, express or implied, free and clear of any claims by the Collateral Agent, all right, title or interest of the Collateral Agent in, to or under the Trademark Collateral of such Grantor.

The Collateral Agent hereby requests that the Commissioner for Trademarks record this Release.

This Release shall be governed by and construed in accordance with the laws of the State of New York.

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized signatory effective as of the date first above written.

ROYAL BANK OF CANADA,  
as Collateral Agent

By: 

Name:

Title: Susan Khokher  
Manager, Agency

[Signature Page to Trademark Release]

TRADEMARK

REEL: 006382 FRAME: 0848

**SCHEDULE A**

**UNITED STATES TRADEMARK REGISTRATIONS AND APPLICATIONS**

<b>OWNER</b>	<b>MARK</b>	<b>SERIAL NO. / REG. NO.</b>	<b>APP DATE / REG. DATE</b>
Impax Laboratories, Inc.	RYTARY & Design	US Reg No. 4782446	May 14, 2013
Amedra Pharmaceuticals LLC	PYNVRM	86274525	May 7, 2014
Amedra Pharmaceuticals LLC	EMVERM	86274536	May 7, 2014
CorePharma L.L.C.	PERIACTIN	86337063	July 15, 2014
Impax Laboratories, Inc.	MYRYTARY	86511726	January 22, 2015
Impax Laboratories, Inc.	IMPAX & Design	86517414	January 28, 2015